| Name | Poolbeg Pharma |
|---|---|
| Epic | POLB |
| Isin | GB00BKPG7Z60 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 7.73p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £38.67 | Debt ratio | n/a |
| Shares in issue | 500.00 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -30.8 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.94 | 52-week high / low | 7.40p / 14.90p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Poolbeg Pharma |
|---|---|
| Address | Queen Mary Bioenterprises Innovation Centre, 42 New Road, London, United Kingdom, E1 2AX |
| Telephone | +44 (0)20 7183 1499 |
| Website | http://www.poolbegpharma.com/ |
| Director | Position |
|---|---|
| Mr Jeremy Skillington | CEO |
| Mr Ian O'Connel | CFO |
| Mr Cathal Friel | Executive Chairman |
| Mr Luke O'Neill | Independent Non-Executive Director |
| Mr Brendan Buckley | Independent Non-Executive Director |
| Mr Edward Gibson | Independent Non-Executive Director |
| Assets £ (m) | 2022 | 2021 |
|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 2.13 | 1.56 |
| Investments and other non-current assets | n/a | n/a |
| Total non-current assets | 2.13 | 1.56 |
| Inventory / work in progress | n/a | n/a |
| Trade and other receivables | 0.96 | 0.51 |
| Cash and equivalents | 16.19 | 20.95 |
| Other current assets and asset held for resale | n/a | n/a |
| Total of all assets | 19.29 | 23.02 |
| Liabilities £ (m) | 2022 | 2021 |
|---|---|---|
| Short term liabilities | 0.97 | 0.44 |
| Long term liabilities | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a |
| Total of all liabilities | 0.97 | 0.44 |
| Net assets £ (m) | 2022 | 2021 |
|---|---|---|
| Net assets | 18.32 | 22.58 |
| Equity £ (m) | 2022 | 2021 |
|---|---|---|
| Share capital | 0.1 | 0.1 |
| Minority interests | n/a | n/a |
| Retained earnings | -7.02 | -2.34 |
| Share premium account | 23.1 | 23.1 |
| Total equity | 18.32 | 22.58 |
| Income £ (m) | 2022 | 2021 |
|---|---|---|
| Turnover | n/a | n/a |
| Operating profit | -4.99 | -2.34 |
| Pre-tax profit | -4.78 | -2.34 |